# US 2008/0214568 A1 · Pharmaceutical Combination Comprising an Antifungal Agent and an Active Substance Selected From Carveol, Eugenol, Thymol, Borneol, Carvacrol, and Alpha- and Beta-Ionones > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2008/0214568 A1 - Document ID: US20080214568A1 - Status: Published application - Kind: A1 - Application number: 11/914,005 - Filed: 2006-05-15 - Published: 2008-09-04 - Earliest claimed: 2005-05-13 - Assignees: Advanced Scientific Developments - Inventors: Adnane Remmal - Web page: https://patentgrep.com/patent/US20080214568A1 ## CPC - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates - A61K 31/05: Phenols {(cannabinoids A61K31/658)} - A61K 31/4196: 1,2,4-Triazoles - A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics - A61P 31/10: Antimycotics - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present invention relates to a pharmaceutical composition. The inventive pharmaceutical composition comprises: at least a first therapeutically-active substance which is selected from carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone and the isomers, derivatives and mixtures thereof; and at least a second therapeutically-active substance which is an antifungal agent. ## Claims ### Claim at position 1 1-12. (canceled) ### Claim 13 A pharmaceutical composition comprising: at least one first therapeutically active substance selected from the group consisting of carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone, and isomers, derivatives, or mixtures thereof; and at least one second therapeutically active substance which is an antifungal agent selected from the group consisting of pyrimidines, azoles, echinocandins and mixtures thereof. ### Claim 14 (depends on 13) The composition according to claim 13, wherein the antifungal agent is selected from 5-fluorocytosine, fluconazole, voriconazole, itraconazole, caspofungin or derivatives and mixtures thereof. ### Claim 15 (depends on 13) The composition according to claim 13, wherein said first therapeutically active substance is eugenol or carvacrol and said second therapeutically active substance is 5-fluorocytosine, fluconazole, voriconazole, itraconazole caspofungin or derivatives and mixtures thereof. ### Claim 16 (depends on 15) The composition according to claim 15, wherein said first therapeutically active substance is carvacrol and said second therapeutically active substance is selected from fluconazole, voriconazole, caspofungin or derivatives and mixtures thereof. ### Claim 17 (depends on 16) The composition according to claim 16, wherein said second therapeutically active substance is fluconazole. ### Claim 18 (depends on 15) The composition according to claim 15, wherein said first therapeutically active substance is eugenol and said second therapeutically active substance is 5-fluorocytosine. ### Claim 19 (depends on 16) The composition according to claim 16, wherein said first and second therapeutically active substances are suspended in an aqueous agar solution. ### Claim 20 (depends on 18) The composition according to claim 18, wherein said first and second therapeutically active substances are suspended in an aqueous agar solution. ### Claim 21 (depends on 16) The composition according to claim 16, wherein said composition does not include any detergent or solvent. ### Claim 22 (depends on 18) The composition according to claim 18, wherein said composition does not include any detergent or solvent. ### Claim 23 A kit comprising: at least one first container containing a first therapeutically active substance selected from the group consisting of carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone and isomers, derivatives or mixtures thereof, and at least one second container containing a second therapeutically active substance which is an antifungal agent selected from the group consisting of pyrimidines, azoles, echinocandins and mixtures thereof. ### Claim 24 (depends on 23) The kit according to claim 23, wherein said second therapeutically active substance is selected from 5-fluorocytosine, fluconazole, voriconazole, itraconazole, caspofungin or derivatives and mixtures thereof. ### Claim 25 (depends on 23) The kit according to claim 23, wherein said first therapeutically active substance is eugenol or carvacrol and wherein said second therapeutically active substance is selected from 5-fluorocytosine, fluconazole, voriconazole, itraconazole, caspofungin or derivatives and mixtures thereof. ### Claim 26 (depends on 23) The kit according to claim 23, wherein said first therapeutically active substance is carvacrol and said second therapeutically active substance is selected from fluconazole, voriconazole, caspofungin, or derivatives and mixtures thereof. ### Claim 27 (depends on 24) The kit according to claim 24, wherein said second therapeutically active substance is fluconazole. ### Claim 28 (depends on 25) The kit according to claim 25, wherein said first therapeutically active substance is eugenol and said second therapeutically active substance is 5-fluorocytosine. ### Claim 29 A method for treating an infection caused by a fungus comprising the simultaneous or sequential administration to a patient having a fungal infection of: at least one first therapeutically active substance selected from the group consisting of carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone and isomers, derivatives, or mixtures thereof, and at least one second therapeutically active substance which is an antifungal agent, selected from the group consisting of pyrimidines, azoles, echinocandins, and mixtures thereof. ### Claim 30 (depends on 29) The method according to claim 29, wherein said second therapeutically active substance is selected from 5-fluorocytosine, fluconazole, voriconazole, itraconazole, caspofungin, or derivatives and mixtures thereof. ### Claim 31 (depends on 29) The method according to claim 29, wherein said first therapeutically active substance is eugenol or carvacrol and said second therapeutically active substance is selected from 5-fluorocytosine, fluconazole, voriconazole, itraconazole, caspofungin, or derivatives and mixtures thereof. ### Claim 32 (depends on 31) The method according to claim 31, wherein said first therapeutically active substance is carvacrol and said second therapeutically active substance is selected from fluconazole, voriconazole, caspofungin, or derivatives and mixtures thereof. ### Claim 33 (depends on 30) The method of claim 30, wherein said second therapeutically active substance is flavozole. ### Claim 34 (depends on 31) The method according to claim 31, wherein said first therapeutically active substance is eugenol and the second therapeutically active substance is 5-fluorocytosine. ### Claim 35 (depends on 29) The method according to claim 29, wherein: between 10 and 200 mg/kg of body weight/day of said first therapeutically active substance; and between 2 and 100 mg/kg of body weight/day of said second therapeutically active substance is simultaneously or sequentially administered to a patient having a fungal infection.